PortalPublikationenEfficacy of Retreatment After Failed Direct-acting Antiviral...

Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections

Standard

Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. / Dietz, Julia; Spengler, Ulrich; Müllhaupt, Beat; Schulze Zur Wiesch, Julian; Piecha, Felix; Mauss, Stefan; Seegers, Barbara; Hinrichsen, Holger; Antoni, Christoph; Wietzke-Braun, Perdita; Peiffer, Kai-Henrik; Berger, Annemarie; Matschenz, Katrin; Buggisch, Peter; Backhus, Johanna; Zizer, Eugen; Boettler, Tobias; Neumann-Haefelin, Christoph; Semela, David; Stauber, Rudolf; Berg, Thomas; Berg, Christoph; Zeuzem, Stefan; Vermehren, Johannes; Sarrazin, Christoph; European HCV Resistance Study Group.

in: CLIN GASTROENTEROL H, Jahrgang 19, Nr. 1, 01.2021, S. 195-198.e2.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Dietz, J, Spengler, U, Müllhaupt, B, Schulze Zur Wiesch, J, Piecha, F, Mauss, S, Seegers, B, Hinrichsen, H, Antoni, C, Wietzke-Braun, P, Peiffer, K-H, Berger, A, Matschenz, K, Buggisch, P, Backhus, J, Zizer, E, Boettler, T, Neumann-Haefelin, C, Semela, D, Stauber, R, Berg, T, Berg, C, Zeuzem, S, Vermehren, J, Sarrazin, C & European HCV Resistance Study Group 2021, 'Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections', CLIN GASTROENTEROL H, Jg. 19, Nr. 1, S. 195-198.e2. https://doi.org/10.1016/j.cgh.2019.10.051

APA

Dietz, J., Spengler, U., Müllhaupt, B., Schulze Zur Wiesch, J., Piecha, F., Mauss, S., Seegers, B., Hinrichsen, H., Antoni, C., Wietzke-Braun, P., Peiffer, K-H., Berger, A., Matschenz, K., Buggisch, P., Backhus, J., Zizer, E., Boettler, T., Neumann-Haefelin, C., Semela, D., ... European HCV Resistance Study Group (2021). Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. CLIN GASTROENTEROL H, 19(1), 195-198.e2. https://doi.org/10.1016/j.cgh.2019.10.051

Vancouver

Dietz J, Spengler U, Müllhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S et al. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. CLIN GASTROENTEROL H. 2021 Jan;19(1):195-198.e2. https://doi.org/10.1016/j.cgh.2019.10.051

Bibtex

@article{c4de7134b3254088ae231780c14207b3,
title = "Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections",
abstract = "Hepatitis C virus infection is causing chronic liver disease, cirrhosis, and hepatocellular carcinoma. By combining direct-acting antivirals (DAAs), high sustained virologic response rates (SVRs) can be achieved. Resistance-associated substitutions (RASs) are commonly observed after DAA failure, and especially nonstructural protein 5A (NS5A) RASs may impact retreatment options.1-3 Data on retreatment of DAA failure patients using first-generation DAAs are limited.4-7 Recently, a second-generation protease- and NS5A-inhibitor plus sofosbuvir (voxilaprevir/velpatasvir/sofosbuvir [VOX/VEL/SOF]) was approved for retreatment after DAA failure.8 However, this and other second-generation regimens are not available in many resource-limited countries or are not reimbursed by regular insurance, and recommendations regarding the selection of retreatment regimens using first-generation DAAs are very important. This study aimed to analyze patients who were re-treated with first-generation DAAs after failure of a DAA combination therapy.",
author = "Julia Dietz and Ulrich Spengler and Beat M{\"u}llhaupt and {Schulze Zur Wiesch}, Julian and Felix Piecha and Stefan Mauss and Barbara Seegers and Holger Hinrichsen and Christoph Antoni and Perdita Wietzke-Braun and Kai-Henrik Peiffer and Annemarie Berger and Katrin Matschenz and Peter Buggisch and Johanna Backhus and Eugen Zizer and Tobias Boettler and Christoph Neumann-Haefelin and David Semela and Rudolf Stauber and Thomas Berg and Christoph Berg and Stefan Zeuzem and Johannes Vermehren and Christoph Sarrazin and {European HCV Resistance Study Group}",
note = "Copyright {\textcopyright} 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.",
year = "2021",
month = jan,
doi = "10.1016/j.cgh.2019.10.051",
language = "English",
volume = "19",
pages = "195--198.e2",
journal = "CLIN GASTROENTEROL H",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections

AU - Dietz, Julia

AU - Spengler, Ulrich

AU - Müllhaupt, Beat

AU - Schulze Zur Wiesch, Julian

AU - Piecha, Felix

AU - Mauss, Stefan

AU - Seegers, Barbara

AU - Hinrichsen, Holger

AU - Antoni, Christoph

AU - Wietzke-Braun, Perdita

AU - Peiffer, Kai-Henrik

AU - Berger, Annemarie

AU - Matschenz, Katrin

AU - Buggisch, Peter

AU - Backhus, Johanna

AU - Zizer, Eugen

AU - Boettler, Tobias

AU - Neumann-Haefelin, Christoph

AU - Semela, David

AU - Stauber, Rudolf

AU - Berg, Thomas

AU - Berg, Christoph

AU - Zeuzem, Stefan

AU - Vermehren, Johannes

AU - Sarrazin, Christoph

AU - European HCV Resistance Study Group

N1 - Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

PY - 2021/1

Y1 - 2021/1

N2 - Hepatitis C virus infection is causing chronic liver disease, cirrhosis, and hepatocellular carcinoma. By combining direct-acting antivirals (DAAs), high sustained virologic response rates (SVRs) can be achieved. Resistance-associated substitutions (RASs) are commonly observed after DAA failure, and especially nonstructural protein 5A (NS5A) RASs may impact retreatment options.1-3 Data on retreatment of DAA failure patients using first-generation DAAs are limited.4-7 Recently, a second-generation protease- and NS5A-inhibitor plus sofosbuvir (voxilaprevir/velpatasvir/sofosbuvir [VOX/VEL/SOF]) was approved for retreatment after DAA failure.8 However, this and other second-generation regimens are not available in many resource-limited countries or are not reimbursed by regular insurance, and recommendations regarding the selection of retreatment regimens using first-generation DAAs are very important. This study aimed to analyze patients who were re-treated with first-generation DAAs after failure of a DAA combination therapy.

AB - Hepatitis C virus infection is causing chronic liver disease, cirrhosis, and hepatocellular carcinoma. By combining direct-acting antivirals (DAAs), high sustained virologic response rates (SVRs) can be achieved. Resistance-associated substitutions (RASs) are commonly observed after DAA failure, and especially nonstructural protein 5A (NS5A) RASs may impact retreatment options.1-3 Data on retreatment of DAA failure patients using first-generation DAAs are limited.4-7 Recently, a second-generation protease- and NS5A-inhibitor plus sofosbuvir (voxilaprevir/velpatasvir/sofosbuvir [VOX/VEL/SOF]) was approved for retreatment after DAA failure.8 However, this and other second-generation regimens are not available in many resource-limited countries or are not reimbursed by regular insurance, and recommendations regarding the selection of retreatment regimens using first-generation DAAs are very important. This study aimed to analyze patients who were re-treated with first-generation DAAs after failure of a DAA combination therapy.

U2 - 10.1016/j.cgh.2019.10.051

DO - 10.1016/j.cgh.2019.10.051

M3 - SCORING: Journal article

C2 - 31706062

VL - 19

SP - 195-198.e2

JO - CLIN GASTROENTEROL H

JF - CLIN GASTROENTEROL H

SN - 1542-3565

IS - 1

ER -